Pulmonary vein ablation competition intensified as new pulsed field ablation (PFA) data presented at Heart Rhythm 2026 continued to show clinical benefits and technology differentiation for treating atrial fibrillation. The update cycle highlights PFA’s push to expand electrophysiologist adoption amid fast-moving performance comparisons across platforms. Med-tech companies used the conference to emphasize energy delivery characteristics and procedural outcomes that distinguish their systems, as the field moves toward broader commercialization and clinician workflows. With PFA still in an active competitive phase, head-to-head comparisons on safety and efficacy remain central to market share. For stakeholders, the key immediate implication is that PFA differentiation is increasingly being defined by detailed clinical readouts rather than early feasibility alone.